Efficacy of lyophilized recombinant human brain natriuretic peptide on chronic heart failure and its influence on cardiac function and plasma NT-proBNP level

Objective To investigate the effect of lyophilized recombinant human brain natriuretic peptide on chronic heart failure and its influence on cardiac function and plasma N-terminal brain natriuretic peptido (NT-proBNP) levels. Methods A total of 120 patients with chronic heart failure in the Central Hospital of Shouzhou from January 2013 to January 2018 were divided into observation group and control group by randomized design, with 60 cases in each group. Both groups were given routine treatment, the control group was treated with nitroglycerin on the basis of conventional treatment. The observation group was treated with lyophilized recombinant human brain natriuretic peptide on the basis of conventional treatment. After 1 week, the clinical efficacy of the two groups was compared. The plasma NT-proBNP and C-reactiveprotein (CRP) levels, left ventricular ejection fraction (LVEF), cardiac index (CI), cardiac output (CO), cardiac function grading and incidences of adverse reactions of the two groups were measured before and after treatment. Results After 1 week of treatment, the total effective rate in the observation group (93.33%) was significantly higher than that in the control group (75.00%, P 0.05). After 1 week of treatment, the plasma levels of NT-proBNP and CRP in the two groups were significantly lower than those before treatment, and those of the observation group were significantly lower than those of the control group (P 0.05). Conclusions Lyophilized recombinant human brain natriuretic peptide is effective on chronic heart failure, which can effectively reduce the plasma NT-proBNP levels, and improve the cardiac function, and it is safe. Key words: Chronic heart failure; Lyophilized recombinant human brain natriuretic peptide; Cardiac function; N-terminal brain natriuretic peptide